Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;21(4):e630-41.
doi: 10.3747/co.21.1966.

Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations

Affiliations

Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations

J Boulanger et al. Curr Oncol. 2014 Aug.

Abstract

Background: Although antineoplastic agents are critical in the treatment of cancer, they can potentially cause hypersensitivity reactions that can have serious consequences. When such a reaction occurs, clinicians can either continue the treatment, at the risk of causing a severe or a potentially fatal anaphylactic reaction, or stop the treatment, although it might be the only one available. The objective of the present work was to evaluate the effectiveness of methods used to prevent and treat hypersensitivity reactions to platinum- or taxane-based chemotherapy and to develop evidence-based recommendations.

Methods: The scientific literature published to December 2013, inclusive, was reviewed.

Results: Premedication with antihistamines, H2 blockers, and corticosteroids is not effective in preventing hypersensitivity reactions to platinum salts. However, premedication significantly reduces the incidence of hypersensitivity to taxanes. A skin test can generally be performed to screen for patients at risk of developing a severe reaction to platinum salts in the presence of grade 1 or 2 reactions, but skin testing does not appear to be useful for taxanes. A desensitization protocol allows for re-administration of either platinum- or taxane-based chemotherapy to some patients without causing severe hypersensitivity reactions.

Conclusions: Several strategies such as premedication, skin testing, and desensitization protocols are available to potentially allow for administration of platinum- or taxane-based chemotherapy to patients who have had a hypersensitivity reaction and for whom no other treatment options are available. Considering the available evidence, the Comité de l'évolution des pratiques en oncologie made recommendations for clinical practice in Quebec.

Keywords: Hypersensitivity reactions; chemotherapy; desensitization; management; platinum salts; skin testing; taxanes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Management algorithm for hypersensitivity reactions to platinum agents. aApply clinical judgment according to observed symptoms. Consider consultation with an allergist, a medical oncologist, or any specialist with desensitization experience; an increase in the infusion time; use or avoidance of premedication; and use of a desensitization protocol. bDesensitization must be conducted under adequate supervision and with the necessary equipment present. po = orally; iv = intravenously.
Figure 2
Figure 2
Management algorithm for hypersensitivity reactions to paclitaxel and docetaxel. aUse protocol with oral administration when possible. bThis product or equivalent. cApply clinical judgment according to observed symptoms. Consider consultation with an allergist, a medical oncologist, or any specialist with desensitization experience; an increase in the infusion time; use or avoidance of premedication; and use of a desensitization protocol. dDesensitization must be conducted under adequate supervision and with the necessary equipment present. po = orally; iv = intravenously; bid = twice daily.

References

    1. Castells M, Sancho–Serra MD, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother. 2012:1575–84. doi: 10.1007/s00262-012-1273-x. - DOI - PMC - PubMed
    1. Pagani M. The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am. 2010;94:835–52. xiii. doi: 10.1016/j.mcna.2010.03.002. - DOI - PubMed
    1. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy. 2002;57(suppl 72):37–40. doi: 10.1034/j.1398-9995.57.s72.7.x. - DOI - PubMed
    1. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:253–62. doi: 10.1385/CRIAI:24:3:253. - DOI - PubMed
    1. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725–32. doi: 10.1634/theoncologist.2008-0012. - DOI - PubMed

LinkOut - more resources